Search research articles
Contact Us
Filters
Showing results (11-20 of 51) with videos related to
Page
of 6
Sort By:
Anticancer Research
|
August 19, 2007
Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model
Brian Higgins, Kenneth Kolinsky, Michael Linn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 11, 2002
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer
William D Fox, Brian Higgins, Krista M Maiese, et al.
Molecular Cancer Therapeutics
|
August 25, 2006
Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T
Manickam Muruganandham, Mihaela Lupu, Jonathan P Dyke, et al.
Cancer Chemotherapy and Pharmacology
|
August 29, 2006
Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models
Jianping Chen, Melissa Smith, Kenneth Kolinsky, et al.
Molecular Cancer Therapeutics
|
January 14, 2009
In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models
Kenneth Kolinsky, Ben-Quan Shen, Yu-E Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2015
Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario
Mark N Levine, Jim A Julian, Philippe L Bedard, et al.
Investigational New Drugs
|
November 18, 2019
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors
Albiruni R Abdul Razak, Wilson H Miller, Geoffrey L Uy, et al.
Anti-Cancer Drugs
|
May 29, 2004
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models
Brian Higgins, Kenneth Kolinsky, Melissa Smith, et al.
Cancer Research
|
June 28, 2011
Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation
Huisheng Wang, Sherif Daouti, Wen-Hui Li, et al.
Molecular Oncology
|
February 15, 2011
High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097
Wei He, Leopoldo Luistro, Daisy Carvajal, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 51) with videos related to
Sort By:
Page
of 6
Anticancer Research
|
August 19, 2007
Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model
Brian Higgins, Kenneth Kolinsky, Michael Linn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 11, 2002
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer
William D Fox, Brian Higgins, Krista M Maiese, et al.
Molecular Cancer Therapeutics
|
August 25, 2006
Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T
Manickam Muruganandham, Mihaela Lupu, Jonathan P Dyke, et al.
Cancer Chemotherapy and Pharmacology
|
August 29, 2006
Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models
Jianping Chen, Melissa Smith, Kenneth Kolinsky, et al.
Molecular Cancer Therapeutics
|
January 14, 2009
In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models
Kenneth Kolinsky, Ben-Quan Shen, Yu-E Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2015
Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario
Mark N Levine, Jim A Julian, Philippe L Bedard, et al.
Investigational New Drugs
|
November 18, 2019
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors
Albiruni R Abdul Razak, Wilson H Miller, Geoffrey L Uy, et al.
Anti-Cancer Drugs
|
May 29, 2004
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models
Brian Higgins, Kenneth Kolinsky, Melissa Smith, et al.
Cancer Research
|
June 28, 2011
Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation
Huisheng Wang, Sherif Daouti, Wen-Hui Li, et al.
Molecular Oncology
|
February 15, 2011
High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097
Wei He, Leopoldo Luistro, Daisy Carvajal, et al.
Page
of 6